Replies to post #233796 on Biotech Values

[IanFromSI]

The companies currently expect to manufacture globally up to 100 million doses by the end of 2020 and potentially more than 1.3 billion doses by the end of 2021, subject to final dose selection from their clinical trial.



All this is starting to be more than ridiculous.

I was under the impression that Governments around the world are only buying an option to get first choice at whatever vaccinations actually get approved after Ph IIIs showing they're both safe and effective. None of the vaccine purchase funds will be given unless and until a safe, effective vaccine is delivered.

Some (different) funds are being spent to ensure that manufacturing capacity is built, ready(approved) and waiting for an approved vaccine.

[semi_infinite]

Huh? That is not even in the round off error of global economic impact. If you were tasked with spending 0.1% (of economic impact) on potential solutions, where would you distribute the money? BTW that 0.1% >> $1.3B.

[jbog]

Miljenko,

Pfizer has agreed to put a ceiling price on the vaccine of $19.50. That's about a quarter of what we pay for the seasonal flu.

That's a bargain.